Natalizumab for the Treatment of Adults with Highly Active Relapsing-Remitting Multiple Sclerosis (TA127)

Technology Appraisal Guidance No. 127

Source: National Institute for Health and Care Excellence

1.1 Natalizumab is recommended as an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by two or more disabling relapses in 1 year, and one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

1.2 People currently receiving natalizumab, but for whom treatment would not have been recommended according to section 1.1 of this guidance, should have the option to continue therapy until they and their clinicians consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

Copies of the document can also be obtained by contacting 0845 003 7783 or emailing and quoting reference number N1324. 

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Natalizumab for the Treatment of Adults with Highly Active Relapsing-Remitting Multiple Sclerosis.
Issue Date: August 2007
Review Date: June 2010

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in